- Home
- PLUG vs HCM Comparison
PLUG vs HCM Comparison
Compare PLUG & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUG
- HCM
- Stock Information
- Founded
- PLUG 1997
- HCM 2000
- Country
- PLUG United States
- HCM Hong Kong
- Employees
- PLUG N/A
- HCM N/A
- Industry
- PLUG Industrial Machinery/Components
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PLUG Energy
- HCM Health Care
- Exchange
- PLUG Nasdaq
- HCM Nasdaq
- Market Cap
- PLUG 3.1B
- HCM 2.6B
- IPO Year
- PLUG 1999
- HCM N/A
- Fundamental
- Price
- PLUG $1.97
- HCM $14.23
- Analyst Decision
- PLUG Hold
- HCM Sell
- Analyst Count
- PLUG 13
- HCM 1
- Target Price
- PLUG $2.15
- HCM $13.75
- AVG Volume (30 Days)
- PLUG 120.3M
- HCM 36.1K
- Earning Date
- PLUG 11-10-2025
- HCM 08-07-2025
- Dividend Yield
- PLUG N/A
- HCM N/A
- EPS Growth
- PLUG N/A
- HCM N/A
- EPS
- PLUG N/A
- HCM 0.53
- Revenue
- PLUG $676,169,000.00
- HCM $602,197,000.00
- Revenue This Year
- PLUG $21.14
- HCM N/A
- Revenue Next Year
- PLUG $25.96
- HCM $15.49
- P/E Ratio
- PLUG N/A
- HCM $5.24
- Revenue Growth
- PLUG 2.53
- HCM N/A
- 52 Week Low
- PLUG $0.69
- HCM $11.51
- 52 Week High
- PLUG $4.58
- HCM $19.50
- Technical
- Relative Strength Index (RSI)
- PLUG 37.02
- HCM 36.32
- Support Level
- PLUG $1.82
- HCM $13.90
- Resistance Level
- PLUG $2.08
- HCM $14.42
- Average True Range (ATR)
- PLUG 0.25
- HCM 0.31
- MACD
- PLUG -0.05
- HCM -0.08
- Stochastic Oscillator
- PLUG 22.27
- HCM 18.29
About PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.